22 unknown. 22 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Unknown 22 |
| Phase 3 | 5 | Unknown 5 |
| Phase 1 | 3 | Unknown 3 |
Follow Angina Pectoris: new trials by email Literature Review of Angina Pectoris trials Research Report on Angina Pectoris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms Allopurinol 300 MG, Placebo oral tablet - Refractory Angina | Phase 2 / Phase 3 | Unknown | Ministry of Health, Brazil | 40 | 2021-03-03 | 2021-02-24 |
| BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome Buqitongluo Granule, Buqitongluo Granule Placebo, Standard care - Stroke, Ischemic, Coronary Artery Disease | Phase 2 | Unknown | Dongzhimen Hospital, Beijing | 432 | 2020-07-22 | 2021-04-01 |
| Rhodiola Rosea for Coronary Microvascular Disease Rhodiola Rosea Capsules, Placebo - Coronary Microvascular Disease | Phase 2 / Phase 3 | Unknown | Qilu Hospital of Shandong University | 114 | 2020-01-01 | 2020-01-06 |
| Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina Xuesaitong soft capsule, Placebo oral capsule - Coronary Heart Disease, Unstable Angina | Phase 2 | Unknown | Jie Wang | 70 | 2017-03-20 | 2017-03-17 |
| Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Unknown | Amaranth Medical Inc. | 70 | 2016-10-01 | 2016-11-25 |
| Hierarchical Treatment Based on Somatization Symptom Checklist Deanxit, Prozac, coronary artery disease treatment - Syndrome X | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 200 | 2015-12-01 | 2020-03-04 |
| Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Unknown | Amaranth Medical Inc. | 60 | 2015-11-01 | 2016-06-08 |
| The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease Rosuvastatin, Olmesartan, Combination - Coronary Syndrome | Phase 2 | Unknown | Samsung Medical Center | 504 | 2015-08-01 | 2015-08-06 |
| Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy UCMSC group - Chronic Ischemic Heart Disease, Heart Failure | Phase 1 / Phase 2 | Unknown | Affiliated Hospital to Academy of Military Medical Sciences | 40 | 2015-05-01 | 2016-03-16 |
| GLP-1 Loading During Elective Percutaneous Coronary Intervention GLP-1, placebo - Angina Pectoris, Myocardial Infarction | Phase 2 | Unknown | Papworth Hospital NHS Foundation Trust | 193 | 2015-03-01 | 2018-06-06 |
| Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Unknown | Amaranth Medical Inc. | 21 | 2015-02-01 | 2016-06-08 |
| To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina Ivabradine, Atenolol - Angina Pectoris | Phase 2 | Unknown | Xintong Pharmacy Company | 336 | 2014-10-01 | 2015-12-07 |
| Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Unknown | Amaranth Medical Inc. | 42 | 2014-09-01 | 2016-06-08 |
| BioFreedom US IDE Feasibility Trial BioFreedom drug coated coronary stent - Ischemic Heart Disease, Stable Angina | Phase 2 / Phase 3 | Unknown | Biosensors Europe SA | 72 | 2014-08-01 | 2015-04-01 |
| Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR loading dose atorvastatin, conventional dose atorvastatin - Stable Angina, Unstable Angina | Phase 2 | Unknown | Central South University | 180 | 2012-12-01 | 2013-01-08 |
| The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease Xuesaitong soft capsule, Xuesaitong soft capsule Placebo - Coronary Heart Disease, Unstable Angina | Phase 2 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 70 | 2012-05-01 | 2014-01-14 |
| Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina Transmyocardial revascularization (TMR) with Holmium YAG laser, Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow. - Angina, Coronary Disease | Phase 2 | Unknown | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 20 | 2010-10-01 | 2010-11-30 |
| Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec), Placebo - Refractory Angina Pectoris | Phase 2 | Unknown | Medispec | 60 | 2009-06-01 | 2013-02-20 |
| Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure Intracoronary administration of autologous ACPs - Angina Pectoris | Phase 1 / Phase 2 | Unknown | TheraVitae Ltd. | 10 | 2007-08-01 | 2007-09-03 |
| To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter pVGI.1(VEGF2) - Angina Pectoris | Phase 2 | Unknown | Corautus Genetics | 404 | 2004-08-01 | 2006-04-20 |
Showing 20 of 22. Sign in to see all of them.
Myocardial Ischemia (9) · Coronary Artery Disease (6) · Angina, Stable (5) · Angina, Unstable (5) · Myocardial Infarction (5) · Coronary Disease (4) · Heart Failure (2) · Microvascular Angina (2) · Cardiovascular Diseases (1) · Ischemic Stroke (1) · Non-ST Elevated Myocardial Infarction (1) · Reperfusion Injury (1)
Heart Diseases (22) · Vascular Diseases (22) · Cardiovascular Diseases (21) · Chest Pain (20) · Neurologic Manifestations (20) · Pain (20) · Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (20) · Myocardial Ischemia (13) · Arterial Occlusive Diseases (6) · Arteriosclerosis (6) · Coronary Disease (6) · Infarction (6) · Ischemia (6)
Allopurinol (1) · Atenolol (1) · Atorvastatin (1) · Exercise (1) · Fluoxetine (1) · Glucagon-Like Peptide 1 (1) · Ivabradine (1) · Rosuvastatin Calcium (1) · Standard of Care (1) · flupentixol, melitracen drug combination (1) · glucagon-like peptide 1 (7-36)amide (1) · olmesartan (1)
Amaranth Medical Inc. (4) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Biosensors Europe SA (1) · Cardium Therapeutics (1) · Central South University (1) · Corautus Genetics (1) · Dongzhimen Hospital, Beijing (1) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Jie Wang (1) · Medispec (1) · Ministry of Health, Brazil (1) · Papworth Hospital NHS Foundation Trust (1) · Qilu Hospital of Shandong University (1) · RenJi Hospital (1)
China (7) · Colombia (3) · Italy (3) · Germany (2) · United States (2) · Brazil (1) · Israel (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Antonio Colombo, MD (3) · Alexander Lind, MD (1) · Bing Liu, M.D (1) · Dan Tzivoni, MD (1) · Guillermo Reyes Copa, Physician Doctor (1) · Hyeon-Cheol Gwon, PhD (1) · Jie Wang (1) · Juan F Granada, MD (1) · Luis Henrique W Gowdak, MD, PhD (1) · Mao Jialiang, Docter (1) · Paul Foster, MD (1) · Rainer Hambrecht, Prof. (1) · Stephen Hoole, MA MD FRCP (1) · Xiaozhong Zhang, M.D (1) · Ying Gao, MD (1)
PMID 17825712, PMID 31277053, PMID 34733163, PMID 35784716
2018 (1)